Defining histamine H2 receptor antagonist response in critically ill patients with heart failure: a machine learning cluster analysis.

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Li-Juan Yang, Fang Yu, Yu Chen, Xin Zhang, Sun-Jun Yin, Ping Wang, Meng-Han Jiang, Hai-Ying Yang, Jia-De Zhu, Ran Xu, Wen-Ke Cai, Gong-Hao He
{"title":"Defining histamine H2 receptor antagonist response in critically ill patients with heart failure: a machine learning cluster analysis.","authors":"Li-Juan Yang, Fang Yu, Yu Chen, Xin Zhang, Sun-Jun Yin, Ping Wang, Meng-Han Jiang, Hai-Ying Yang, Jia-De Zhu, Ran Xu, Wen-Ke Cai, Gong-Hao He","doi":"10.1007/s11096-025-01892-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent studies showed histamine H2 receptor antagonists (H2RAs) exposure was associated with reduced mortality in heart failure (HF) patients. However, specific HF patients who are sensitive to H2RAs exposure or not are yet to be further defined.</p><p><strong>Aim: </strong>This study aimed to identify HF patient characteristics that may benefit from H2RAs exposure.</p><p><strong>Method: </strong>Neural network-based variational autoencoders and Gaussian Mixture Model (GMM) clustering methods were employed to classify the critically ill patients with HF exposed to H2RAs based on Medical Information Mart for Intensive Care III and IV databases. Binary logistic and multivariable Cox regression analysis based on propensity score matching (PSM) were employed to estimate the association between H2RAs exposure of each cluster and all-cause mortality of included patients.</p><p><strong>Results: </strong>A total of 9,585 H2RAs users among 23,855 included HF patients were identified into four clusters according to GMM clustering: cluster 1 (combined with acute kidney failure, septic shock, and pneumonia), cluster 2 (combined with atrial fibrillation), cluster 3 (combined with coronary artery disease (CAD) and/or had higher urine output), and cluster 4 (co-administered with calcium-antagonists). The cluster 3 patients were significantly associated with reduced all-cause mortality compared with non-H2RAs users after PSM, which were further validated in 14,280 HF patients from the large multi-center electronic intensive care unit Collaborative Research Database (eICU-CRD).</p><p><strong>Conclusion: </strong>Histamine H2 receptor antagonist exposure was more sensitive in HF patients who were combined with CAD. Furthermore, male HF patients or those with higher urine output were also sensitive to H2RAs exposure.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11096-025-01892-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Recent studies showed histamine H2 receptor antagonists (H2RAs) exposure was associated with reduced mortality in heart failure (HF) patients. However, specific HF patients who are sensitive to H2RAs exposure or not are yet to be further defined.

Aim: This study aimed to identify HF patient characteristics that may benefit from H2RAs exposure.

Method: Neural network-based variational autoencoders and Gaussian Mixture Model (GMM) clustering methods were employed to classify the critically ill patients with HF exposed to H2RAs based on Medical Information Mart for Intensive Care III and IV databases. Binary logistic and multivariable Cox regression analysis based on propensity score matching (PSM) were employed to estimate the association between H2RAs exposure of each cluster and all-cause mortality of included patients.

Results: A total of 9,585 H2RAs users among 23,855 included HF patients were identified into four clusters according to GMM clustering: cluster 1 (combined with acute kidney failure, septic shock, and pneumonia), cluster 2 (combined with atrial fibrillation), cluster 3 (combined with coronary artery disease (CAD) and/or had higher urine output), and cluster 4 (co-administered with calcium-antagonists). The cluster 3 patients were significantly associated with reduced all-cause mortality compared with non-H2RAs users after PSM, which were further validated in 14,280 HF patients from the large multi-center electronic intensive care unit Collaborative Research Database (eICU-CRD).

Conclusion: Histamine H2 receptor antagonist exposure was more sensitive in HF patients who were combined with CAD. Furthermore, male HF patients or those with higher urine output were also sensitive to H2RAs exposure.

确定危重心衰患者组胺H2受体拮抗剂反应:机器学习聚类分析。
背景:最近的研究表明,组胺H2受体拮抗剂(H2RAs)暴露与心力衰竭(HF)患者死亡率降低有关。然而,具体的HF患者是否对H2RAs暴露敏感还有待进一步确定。目的:本研究旨在确定可能受益于H2RAs暴露的HF患者特征。方法:采用基于神经网络的变分自编码器和高斯混合模型(GMM)聚类方法,基于重症监护医学信息集市III和IV数据库对暴露于H2RAs的HF危重患者进行分类。采用二元逻辑分析和基于倾向评分匹配(PSM)的多变量Cox回归分析来估计每个聚类的H2RAs暴露与纳入患者全因死亡率之间的关系。结果:在23,855例纳入的HF患者中,共有9,585名H2RAs使用者根据GMM聚类被确定为四组:第1组(合并急性肾衰竭、感染性休克和肺炎)、第2组(合并心房颤动)、第3组(合并冠状动脉疾病(CAD)和/或尿量较高)和第4组(与钙拮抗剂联合使用)。与未使用h2ras的患者相比,第3组患者在PSM后的全因死亡率显著降低,这一点在来自大型多中心电子重症监护病房合作研究数据库(eICU-CRD)的14,280例HF患者中得到了进一步验证。结论:组胺H2受体拮抗剂暴露对合并冠心病的心衰患者更为敏感。此外,男性HF患者或尿量较高的患者也对H2RAs暴露敏感。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
8.30%
发文量
131
审稿时长
4-8 weeks
期刊介绍: The International Journal of Clinical Pharmacy (IJCP) offers a platform for articles on research in Clinical Pharmacy, Pharmaceutical Care and related practice-oriented subjects in the pharmaceutical sciences. IJCP is a bi-monthly, international, peer-reviewed journal that publishes original research data, new ideas and discussions on pharmacotherapy and outcome research, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics, the clinical use of medicines, medical devices and laboratory tests, information on medicines and medical devices information, pharmacy services research, medication management, other clinical aspects of pharmacy. IJCP publishes original Research articles, Review articles , Short research reports, Commentaries, book reviews, and Letters to the Editor. International Journal of Clinical Pharmacy is affiliated with the European Society of Clinical Pharmacy (ESCP). ESCP promotes practice and research in Clinical Pharmacy, especially in Europe. The general aim of the society is to advance education, practice and research in Clinical Pharmacy . Until 2010 the journal was called Pharmacy World & Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信